Breast cancer
61,214 new cases in France in 2023 1
What is it?
Breast cancer develops when cells in the mammary gland multiply abnormally. It most often starts in the ducts that carry milk (ductal cancer), and less often in the lobules that produce it (lobular cancer). A distinction is made between “in situ” forms, which remain within the duct, and “invasive” forms 2.
How it develops
At first, the abnormal cells remain within the duct. They may then cross its wall, reach the lymph nodes in the armpit and, later, other organs (bones, lungs, liver) 2.
How long does it take to develop?
The phase during which a mammogram can detect the tumor before any symptoms lasts an average of 2 to 7 years, depending on age and breast density 3. Screening aims to make use of this window.
Risk factors
- Age: about 8 in 10 cases occur after age 50
- A family history (mother, sister, daughter) or personal history of breast cancer
- A genetic predisposition (BRCA1, BRCA2…), in 2 to 5 % of cases
- Hormonal factors: early periods, late menopause, no pregnancies or a first pregnancy after age 35
- Alcohol, tobacco, excess weight after menopause, physical inactivity
- Menopausal hormone therapy taken for more than 5 years
What helps protect you: Regular physical activity, little or no alcohol, a stable weight 4.
Signs that should prompt a visit to your doctor
In the early stages
- Often no signs
As it progresses
- A lump in the breast or under the arm
- Changes to the skin or nipple
At an advanced stage
- Signs vary depending on the organs affected
These signs do not mean you have cancer: they may have other causes. Unsure? Talk to your doctor.
⁵A lump in the breast, a hard lymph node under the arm, discharge from only one nipple, a nipple that turns inward, skin with an “orange peel” appearance. Most of these changes have a benign cause, but they are worth discussing with a doctor 6.
Detected early or at a later stage
When detected early, the cancer is confined to the breast (localized stage): this accounts for 64 % of cases in the United States. At the regional stage, nearby lymph nodes are affected (27 %). At the distant stage, metastases are present (6 %) 7.
5-year survival by stage
In France, 5-year net survival: 88 % 8.
Approximate correspondence with the clinical classification (TNM/FIGO); this varies depending on the tumour's characteristics.
Screening in France
Yes. A mammogram every 2 years, from ages 50 to 74, covered with no upfront payment. Participation: 47,5 % in 2025 9.
Monitoring for people at risk
An annual clinical breast examination from age 25. For women at high or very high risk (particularly BRCA carriers), tailored follow-up with annual MRI and mammography from age 30 10.

Prevonco is currently available in France only.
An aid to the early detection of 16 cancers
No prescription needed, for people without symptoms. If you have an unexplained symptom, see your doctor first.
Pre-register for free →Frequently asked questions
Do I need a prescription?
No. With Prevonco, you do not need a prescription: after ordering online, a unique code gives you access to the test at one of our partner laboratories. In France, some laboratory tests can be carried out at your request, without a prescription.
No prescription, but still a doctor: they remain central to the process. Your result is sent to the doctor you selected from our panel, who will explain it during a 30-minute video consultation, included whatever the result.
Are you receiving care for cancer? Speak directly to your oncologist: they can prescribe this test without going through Prevonco.
For any questions about your situation, or if you have symptoms, your doctor remains your first point of contact.
What if my level is high?
A high level tends to be a strong signal. It is not a conclusion: its cause needs to be investigated with a doctor.¹¹
Your result is sent to the doctor you selected from our panel. They will explain it during the 30-minute video consultation included in the price. Further investigations prescribed by a doctor can help identify the cause.¹¹
What if the level is intermediate? It may not be related to cancer (smoking, an inflammatory condition, etc.). Other blood tests may be suggested; if they are normal, a repeat check is planned at 12 months. You will never be left to face your result alone.¹¹
What if my level is low?
That is reassuring, but no test is perfect: a low level does not rule everything out.¹¹
If you have no symptoms, no specific follow-up is recommended after a low result. The risk of a false negative varies by cancer type.¹¹
Your doctor, who is trained in functional medicine and specialises in prevention, will help you explore any concerns or symptoms during the 30-minute video consultation.¹¹
Keep up with your usual screening: respond to invitations for organised screening programmes, and see your doctor if a symptom appears.¹¹
How long will it take to get my results?
The laboratory analysis takes 30 days. Your full results are presented by a doctor trained in functional medicine during a 30-minute consultation included in your package.
You choose the date and time slot that suit you for this appointment.
Prevonco is currently available in France only.
An aid to the early detection of 16 cancers
No prescription needed, for people without symptoms. If you have an unexplained symptom, see your doctor first.
Pre-register for free →General information for educational purposes: it does not replace your doctor's advice. An aid to early detection: it does not replace organised screening, imaging tests or your doctor's advice.
Sources
- 1.INCa, Panorama des cancers en France, 2026
- 2.American Cancer Society, What Is Breast Cancer?
- 3.Geurts et al., Epidemiology and Health, 2022 (duration of the detectable preclinical phase)
- 4.Santé.fr / INCa, facteurs de risque du cancer du sein
- 5.Institut Curie ; INCa (cancer.fr, 2025 ; guide « Du diagnostic au suivi », 2016)
- 6.American Cancer Society, signes du cancer du sein
- 7.NCI SEER, Cancer Stat Facts – Female Breast Cancer (2016-2022)
- 8.Santé publique France, survie des personnes atteintes de cancer 1989-2018
- 9.Santé publique France, participation au dépistage organisé du cancer du sein 2024-2025
- 10.HAS 2014, dépistage en présence de facteurs de risque (VIDAL summary)
- 11.biodena.care